Abbott Laboratories vs. NewAmsterdam Pharma Company N.V. Ordinary Shares
ABT
Abbott Laboratories
$101.29 +0.22%
VS NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares
$22.58 -0.70%
Abbott Laboratories (ABT) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| ABT | NAMS | |
|---|---|---|
| Market Cap | $175.27 billion | $2.70 billion |
| Revenue (TTM) | $46.59 billion | $7.12 million |
| Net Income (TTM) | $5.42 billion | $-259,504,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | NAMS | |
|---|---|---|
| P/E Ratio | 32.78 | — |
| Price / Book | 3.39 | 4.27 |
| Price / Sales | 3.76 | 379.04 |
ABT leads on 2 of 2 valuation factors.
Profitability
| ABT | NAMS | |
|---|---|---|
| Net Margin | 11.65% | -3644.21% |
| Return on Equity | 10.48% | -41.10% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | NAMS | |
|---|---|---|
| Dividend Yield | 2.49% | — |
| Payout Ratio | 81.55 | — |
ABT and NAMS split the dividend factors evenly.
Risk & Sentiment
| ABT | NAMS | |
|---|---|---|
| Short Interest | 0.57% | 0.01% |
NAMS leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, NAMS overview, NAMS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.